Fmr LLC Raises Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Fmr LLC increased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 27.5% in the third quarter, Holdings Channel.com reports. The firm owned 18,401 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,972 shares during the period. Fmr LLC’s holdings in ANI Pharmaceuticals were worth $1,098,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ANIP. Texas Permanent School Fund Corp boosted its stake in ANI Pharmaceuticals by 1.3% in the 2nd quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after buying an additional 178 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in shares of ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after acquiring an additional 200 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 4.7% during the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after acquiring an additional 211 shares during the period. Thrivent Financial for Lutherans boosted its position in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares during the last quarter. Finally, New York State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 1.7% in the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Truist Financial increased their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Raymond James boosted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Trading Down 0.4 %

NASDAQ:ANIP opened at $56.36 on Tuesday. The business’s 50-day moving average is $58.02 and its two-hundred day moving average is $60.24. The firm has a market capitalization of $1.19 billion, a PE ratio of -102.47 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a 12 month low of $51.88 and a 12 month high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s revenue was up 12.5% on a year-over-year basis. During the same period last year, the business posted $1.05 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares in the company, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,731 shares of company stock worth $2,015,861 over the last 90 days. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.